Oasmia Pharma Names Fredrik Gynnerstedt CFO, Effective Dec. 1

(RTTNews) - Oasmia Pharmaceutical AB (OASM), a Swedish developer of a new generation of drugs within human and veterinary oncology, announced Wednesday the appointment of Fredrik Gynnerstedt to the position of Chief Financial Officer.

Gynnerstedt's employment begins on December 1, 2016 and he will be a member of Oasmia's management team.

Gynnerstedt, who holds 15 years' experience in international business administration and activities, was employed previously as the Director of Collaboration at Karnov Group.

Prior to that role, he served as Chief Financial Officer for Bringwell AB, and as auditor and consultant at Ernst & Young.

Gynnerstedt said, "I'm happy to join the team at Oasmia, a company currently in an exciting phase as it pursues global commercialization via its robust pipeline of pharmaceutical products."

In Stockholm, Oasmia shares were declining 4.81 percent to trade at 9.90 Swedish kronor.